A unique opportunity

Optimo Medical AG is currently offering the unique opportunity for medium- to long-term financiers, to invest into a serious and down-to-earth venture. The timing could not be better: CE certification and market entry are just a step away, risks are under control. The gigantic market of cataract surgery ($22billion), combined with our highly scalable business model, makes us a very attractive case for investors seeking to invest into the smart, digital future of hi-medical-technology. 

Your contact:
Dr. Harald P Studer, PhD (This email address is being protected from spambots. You need JavaScript enabled to view it.);
dir: +41 (0)32 513 6793, mob: +41 (0)76 588 4619

The bigger picture

Optimo Medical AG is a company in the booming medtech industry. More specifically, in the field of eye care and eye surgery. The eye was the organ which attracted the single most venture capital in 2013, 2014, and 2015. But the eye is more than a short term hit. In the last 15 years, the eye has had a strong investment history. But not only the eyes have had a strong run, also lasers and diagnostic devices to treat and examine the eye have developed significantly in the last 10 years. With those developments the market for eye surgery tools is ready for significant payoffs.


Venture capital investment history of the eye. Wall Street Journal "The Human Body, According to Venture Capitalists", 2015.

In 2015, a total of $709m was raised for product development by ophthalmic firms. Not only have large amounts been raised, 2015 was a record breaking year for mergers & acquisitions in ophthalmology, as the biggest ever price for a company was paid when Actavis acquired Allergan for $70.5b in March, and as the total number of firms acquired, set a new record in 2015.